Supriya Lifescience Limited has informed the Exchange regarding a press release dated August 14, 2025, titled "Press Release for the Unaudited Financial Results for the quarter ended June 30, 2025".
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience, an API manufacturer exporting to 86+ countries, reported Q1 FY26 revenue of Rs 145.07 crore, down 9.7% from Rs 160.63 crore in Q1 FY25. EBITDA fell to Rs 51.7 crore with margin contracting to 35.6% (from 38.9%), and profit after tax dropped to Rs 34.79 crore (margin 24.0% vs 27.8%). Quarterly EPS stood at Rs 4.3 versus Rs 5.5. Management attributed the dip to a delayed production campaign at the Lote facility, where essential repair and maintenance work was undertaken. On the positive side, the anaesthetic segment now contributes 53% of revenue, European markets have grown to 41% of sales, and capacity utilisation improved from 70% to 76%. The company has acquired three land parcels to support growth and expects the Ambernath site to begin commercial production in Q4 FY26.
Near-term results are weak on both revenue and profitability, likely to weigh on the stock, but strong margins despite the maintenance shutdown and management's guidance of ~20% growth targeting Rs 1,000 crore revenue by FY27 could limit the downside and support a recovery narrative in H2 FY26.